



SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092
E-mail : compliance@sudarshanpharma.com Website : www.sudarshanpharma.com
Board Line : + 91-22-42221111 / 42221116 (100 line) CIN : L51496MH2008PLC184997

SPIL/CS/SE/2024-2025/47

Date: November 29, 2024

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023

Sub: Intimation for acquisition of the ordinary shares of Sudarshan Pharma Industries Private Limited, Singapore.
Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company have, on 28th November, 2024 inter-alia, approved to acquire 10,000 ordinary shares of Singapore Dollar 1/- each of Sudarshan Pharma Industries Private Limited, a company incorporated in Singapore (Unique Entity Number: 202327475M) (100% of the paid-up share capital of Sudarshan Pharma Industries Private Limited). Upon completion of the acquisition, Sudarshan Pharma Industries Private Limited, Singapore would become a wholly-owned subsidiary of the Company.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given in Annexure A.

This is for your information and record.

Thanks & Regards,

Yours faithfully,

For, Sudarshan Pharma Industries Limited

Hemal Mehta
Chairman & Managing Director

Encl: As above



SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Borivali (west) Mumbai - 400092

E-mail : compliance@sudarshanpharma.com Website : www.sudarshanpharma.com

Board Line : + 91-22-42221111 / 42221116 (100 line) CIN : L51496MH2008PLC184997

Annexure A

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given below:

Sr. no.	Details to be Provided	Information
1	Name of the target entity, details in brief such as size, etc.	Name: Sudarshan Pharma Industries Private Limited (Company Incorporated in Singapore) (As on 31 st March 2024) Authorised Share Capital: 10,000/- (Singapore Dollars) Paid up Share Capital: 10,000/- (Singapore Dollars)
2	Whether the acquisition would fall within related party transactions and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length'	No. Since the Company is acquiring 10,000 ordinary shares of Sudarshan Pharma Industries Private Limited, Singapore which are presently being held by Mr. Amar Ashok Vyas, the acquisition would not fall within the purview of related party transactions.
3	Industry to which the entity being acquired belongs.	Sudarshan Pharma Industries Private Limited is in the business of wholesale trade of variety of goods without a dominant product including wholesale business of basic industrial chemicals.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The acquisition will help the Company to expand its business operations in Singapore and other neighbouring countries.
5	Brief details of governmental or any regulatory approvals "required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	3 months from the date of entering into Share Purchase Agreement



SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail : compliance@sudarshanpharma.com Website : www.sudarshanpharma.com

Board Line : + 91-22-42221111 / 42221116 (100 line) CIN : L51496MH2008PLC184997

7	Nature of Consideration whether Cash consideration or share swap and details of the same	To be subscribed in cash								
8	Cost of acquisition or the price at which the shares are acquired.	Singapore Dollars 10,000/-								
9	Percentage of shareholding control acquired and /or number of shares acquired	10,000 ordinary shares of Re. 1/- Singapore Dollar each (100 % of the paid-up share capital) of Sudarshan Pharma Industries Private Limited.								
10	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p><u>Brief background:</u></p> <p>Sudarshan Pharma Industries Private limited was incorporated on 12th July, 2023.</p> <p>Sudarshan Pharma Industries Private limited is in the business of wholesale trade of variety of goods without a dominant product including wholesale business of basic industrial chemicals.</p> <p>Last 3 years' turnover details:</p> <table><thead><tr><th>Financial Year</th><th>(Amount in Lakhs)</th></tr></thead><tbody><tr><td>2023-2024</td><td>Nil</td></tr><tr><td>2022-2023</td><td>Not Applicable</td></tr><tr><td>2021-2022</td><td>Not Applicable</td></tr></tbody></table> <p>Countries in which the acquired entity has presence: Singapore</p>	Financial Year	(Amount in Lakhs)	2023-2024	Nil	2022-2023	Not Applicable	2021-2022	Not Applicable
Financial Year	(Amount in Lakhs)									
2023-2024	Nil									
2022-2023	Not Applicable									
2021-2022	Not Applicable									

For, Sudarshan Pharma Industries Limited

Hemal Vasantrai Mehta
Digitally signed by Hemal Vasantrai Mehta
Date: 2024.11.29 18:13:43 +05'30'

Hemal Mehta
Chairman & Managing Director